期刊首页 优先出版 当期阅读 过刊浏览 作者中心 关于期刊 English

《医学前沿(英文)》 >> 2019年 第13卷 第2期 doi: 10.1007/s11684-018-0627-y

Mesenchymal stem cells and immune disorders: from basic science to clinical transition

Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; School of Basic Medicine, Peking Union Medical College; Peking Union Medical College Hospital; Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences, Beijing 100005, China

录用日期: 2018-07-31 发布日期: 2018-07-31

下一篇 上一篇

摘要

As a promising candidate seed cell type in regenerative medicine, mesenchymal stem cells (MSCs) have attracted considerable attention. The unique capacity of MSCs to exert a regulatory effect on immunity in an autologous/allergenic manner makes them an attractive therapeutic cell type for immune disorders. In this review, we discussed the current knowledge of and advances in MSCs, including its basic biological properties, i.e., multilineage differentiation, secretome, and immunomodulation. Specifically, on the basis of our previous work, we proposed three new concepts of MSCs, i.e., “subtotipotent stem cell” hypothesis, MSC system, and “Yin and Yang” balance of MSC regulation, which may bring new insights into our understanding of MSCs. Furthermore, we analyzed data from the Clinical Trials database (http://clinicaltrials.gov) on registered clinical trials using MSCs to treat a variety of immune diseases, such as graft-versus-host disease, systemic lupus erythematosus, and multiple sclerosis. In addition, we highlighted MSC clinical trials in China and discussed the challenges and future directions in the field of MSC clinical application.

相关研究